Skip to main content
. 2023 Apr 4;13(4):646. doi: 10.3390/biom13040646

Figure 6.

Figure 6

Proinflammatory pathways upregulated in cardiomyopathies and targets for molecular therapy. Suitable molecular targets to mitigate myocardial inflammation in primary cardiomyopathies are shown, along with the proinflammatory pathways most commonly involved. Biological agents and immunomodulatory drugs currently available are in evidence.